Wall Street Zen Downgrades Outset Medical (NASDAQ:OM) to Sell

Outset Medical (NASDAQ:OM) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

A number of other research firms have also commented on OM. BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Outset Medical presently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Outset Medical Stock Performance

OM opened at $4.65 on Friday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The firm has a market cap of $84.40 million, a PE ratio of -0.36 and a beta of 2.07. The business has a fifty day simple moving average of $4.44 and a 200-day simple moving average of $9.70. Outset Medical has a fifty-two week low of $3.10 and a fifty-two week high of $21.98.

Insider Buying and Selling at Outset Medical

In related news, CEO Leslie Trigg sold 11,794 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the completion of the sale, the chief executive officer owned 107,823 shares of the company’s stock, valued at approximately $552,053.76. This trade represents a 9.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marc Nash sold 5,375 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $27,520.00. Following the completion of the transaction, the executive vice president owned 42,785 shares in the company, valued at $219,059.20. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 35,989 shares of company stock valued at $180,073 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Outset Medical

Large investors have recently bought and sold shares of the business. Legal & General Group Plc bought a new position in Outset Medical during the second quarter valued at about $34,000. Ameritas Investment Partners Inc. acquired a new position in shares of Outset Medical during the 2nd quarter valued at about $35,000. BNP Paribas Financial Markets raised its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Outset Medical in the 2nd quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund acquired a new stake in Outset Medical in the 2nd quarter worth approximately $108,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.